REG - OptiBiotix Health - First order from US weight management brand

OptiBiotix HealthAnnouncement

15/04/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250415:nRSO9670Ea&default-theme=true

RNS Number : 9670E  OptiBiotix Health PLC  15 April 2025

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

First order from leading US weight management brand

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
products which reduce hunger and food cravings, enhance the gut microbiome,
and sweet fibres as healthy sugar substitutes, announces it has received its
first order from a leading weight management brand in the United States of
America ("USA").

 

The order is for SlimBiome® as an ingredient which will be incorporated into
a range of flavoured drinks, similar to SlimBiome Medical, which reduces
hunger. The products will be included in one of the USA's leading weight
management brands. SlimBiome® has undergone multiple human studies which show
its ability to reduce hunger and food cravings which leads to lower calorie
intake. OptiBiotix has been working with this brand for over 18 months to
carry out human studies which allows the brand to make health claims of hunger
control on its products in the USA. Scientifically substantiated health claims
help to differentiate these products from others on the market. In the
changing landscape of this market, brought about by the anti-obesity drugs,
consumers are actively looking for natural, science backed appetite support
products. SlimBiome® meets this developing trend.

 

OptiBiotix expect further orders for a second product, a tablet containing
SlimBiome®, within H1 2025. Whilst it is too early to understand the
potential scale of the opportunity, this news is material in that it
represents the inclusion of SlimBiome® in products of one of the USA's most
popular weight management brands. Further information on the partner and brand
will be announced on launch which the Company anticipates will be in H1 2025.
However, the Company reminds investors that launch timescales are dictated by
the brand owner and these can be subject to change.

 

Stephen O'Hara, CEO of OptiBiotix Health plc said: "We are pleased to announce
the first order for the use of SlimBiome® in one of the USA's leading weight
management brands. The use of SlimBiome® has allowed the brand to make health
claims of hunger control on its products which differentiate them from other
products on the market. We anticipate more orders and product launches with
this brand as it extends the range of products containing SlimBiome® in the
USA market in 2025.

 

"Following the launch of the anti-obesity drugs, natural non-drug alternatives
to reduce hunger and cravings are actively being sought by consumers. This
announcement demonstrates that the science and multiple human studies carried
out on SlimBiome® is now attracting the interest of major brands around the
world."

 

The Directors of the Company are responsible for the release of this
announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                          www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman                                                  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)           Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)            Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd
 Anna Dunphy                                    Mob: 07876 741 001

 

 

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCIIMATMTIBBAA